Akoya Biosciences (NASDAQ:AKYA) Bolsa

Akoya Biosciences

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Akoya Biosciences Inc

Wells Fargo analyst Mike Mayo maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Equal-Weight and lowers the price target from $67 to $55.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Comerica, Lowers Price Target to $55

Contracts

OPTX

Syntec Optics Secures $5.2M On New Orders For Defense Night Vision Goggle Optics

Wells Fargo analyst Elyse Greenspan maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Equal-Weight and raises the price target from $69 to $70.

Wells Fargo Maintains Equal-Weight on WR Berkley, Raises Price Target to $70

New 5 MW Hosting Deal Highlights Growing Demand for Sustainable Bitcoin Infrastructure
Soluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, announced today that it has signed a two-year hosting agreement with Blockware, one of North America's leading crypto mining infrastructure and services providers.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250422128504/en/">https://www.businesswire.com/news/home/20250422128504/en/</a>
Soluna Signs Deal with Blockware at Project Dorothy 2, Expanding Bitcoin Hosting Business
Under the terms of the agreement, Blockware will deploy approximately 1,500 of its next-generation S21+ mining units at Soluna's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.solunacomputing.com%2Fnews%2Fsoluna-powers-up-project-dorothy-2%2F&amp;esheet=54241444&amp;newsitemid=20250422128504&amp;lan=en-US&amp;anchor=Project+Dorothy+2&amp;index=1&amp;md5=7e369b26be90ecf46ed06a091c0ba74c">Project Dorothy 2</a> data center in Texas. The deployment, targeting an initial deployment of 5 megawatts (MW), began on April 21, 2025, with operations expected to fully ramp up by June 1, 2025. Blockware anticipates deploying 250 PH/s to 350 PH/s at the site.

SLNH

Soluna Has Signed A 2-Year Hosting Agreement With Blockware; Blockware Will Deploy ~1,500 Of Its Next-generation S21+ Mining Units At Soluna's Project Dorothy 2 Data Center In Texas

Syntec Optics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>), a leading provider of technology to defense, biomedical, communications and consumer industry leaders, today announced it has secured orders totaling nearly $5.2 million so far this year for optics and optomechanicals supporting the latest generation of advanced night vision goggles used in the U.S. defense to keep our soldiers out of harm's way. Syntec's mission-critical optics make the helmet-mounted goggle lighter to reduce neck trauma for soldiers.
As a strong start to the year, Syntec has already delivered nearly $0.9M in product. Syntec will continue to deliver and build upon its multi-year involvement in this key defense program, where it has supplied vital low-weight, high-performance manufacturing technology since initial development phases began in 2018. The nearly $5.2 million in recent orders in 2025 highlights Syntec's expanded role in providing a comprehensive suite of products crucial for the functionality of advanced binocular systems, known for enhancing situational awareness and incorporating fused thermal imaging capabilities.
"We are pleased to see continued strong demand for this critical night vision program, " said Matt Carey, head of Business Development and Delivery at Syntec Optics. "This demonstrates the ongoing trust placed in Syntec's ability to deliver products that meet the rigorous performance standards required for national defense."
Mike Ransford, Site Leader at Syntec Optics, commented, "The consistent order flow, now totaling close to $5.2 million this year, corresponds with the active fielding and sustained need for these advanced night vision capabilities. Our ability to provide a broad spectrum of products, from foundational optics to complex sub-assemblies, positions Syntec as a comprehensive partner for this long-term program."

Syntec Optics Secures Orders Totaling ~$5.2M So Far This Year For Optics And Optomechanicals Supporting The Latest Generation Of Advanced Night Vision Goggles Used In  U.S. Defense

Wells Fargo analyst Roger Read maintains Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) with a Equal-Weight and raises the price target from $45 to $46.

Wells Fargo Maintains Equal-Weight on Ovintiv, Raises Price Target to $46

Baird analyst David George maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Neutral and lowers the price target from $58 to $55.

ZION

Baird Maintains Neutral on Zions Bancorp, Lowers Price Target to $55

Wells Fargo analyst Zachary Fadem maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Equal-Weight and lowers the price target from $52 to $45.

CAKE

Wells Fargo Maintains Equal-Weight on Cheesecake Factory, Lowers Price Target to $45

<a href="https://www.globenewswire.com/Tracker?data=8veCI3g1em0T5GGwxfmnLVIVtYKMBB8pXLtaciIKxM9A0i2WsW8FFPkjcfoqrnlwbi26Zn5XKQ2SR-yoxGrPZB0HR-TJFI44CC-rcBC4XiY=">CERo Therapeutics Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.
The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 million of cash that may be funded at one or more additional closings, at the election of the investors. &nbsp;CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly.&nbsp; The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway.&nbsp;

Financing

CERO

CERo Therapeutics Announces Up To $8M In Series D Financing

MCLEAN, Va., April 22, 2025 (GLOBE NEWSWIRE) -- Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) ("Cycurion" or the "Company"), a trusted leader in IT cybersecurity solutions and AI, announces a partnership with LSV-TECH International Consortium for Digital Transformation and Technological Innovation to expand the new Managed Security Services Platform (MSSP) Cyber Shield into Latin America and strengthen cross-border interconnections globally.
The partnership is commencing through a pilot program with several Colombian universities to showcase the new MSSP Cyber Shield. LSV-TECH has long-term, established relationships with several higher education institutions in Colombia, wherein strategic alliances aimed at developing digital talent and strengthening capabilities in new technologies have been developed. Its academic partners include the Popular University of Cesar, the University of La Guajira, the University of North Barranquilla, the University of Valle Cali, the Intenalco University Cali, the Antioquia University Medellin, the University of Cartagena, the Major University Institution of Cartagena, the Rafael Núñez University, the Technological University of Bolívar, and the University of Sinú. These relationships allow for joint efforts in applied research, professional internships, training in emerging technologies, AI, and open innovation programs.

CYCU

Cycurion Partners With LSV-TECH International Consortium For Digital Transformation And Technological Innovation To Expand MSSP Cyber Shield Into Latin America

Construction on Auto Clubhouse Charlotte is Expected to Commence in Q3 2025
Lantana, FL, April 22, 2025 (GLOBE NEWSWIRE) -- JFB Construction Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFB#NASDAQ">JFB</a>), a construction company focused on commercial, retail, and residential property development, today announced plans to commence, in Q3 2025, the largest single commercial construction project in company history. Pursuant to the Agreement, JFB will serve as the prime contractor to manage design and construction of Auto Clubhouse in Charlotte, North Carolina, a 103,000 square foot warehouse for car storage that contains 42 luxury auto condo bays and a 40,000 square foot storage building for luxury vehicles.
"Our general commercial construction division that has been a key component of our past growth will continue to be instrumental in the future growth of our business which represents a significant portion of our total revenue," said CEO Joseph F. Basile, III. "The Auto Clubhouse project is our largest single commercial / industrial construction project to date, in which we will serve as the prime contractor. This is a 103,000 square foot warehouse and condos to store luxury vehicles. We believe that this industrial project will open the doors for more industrial projects in the future. Our general commercial construction division will continue to focus on the Southern Atlantic region of the United States in the short to mid-term, focusing on regions where we forecast continued state-to-state migration and expanding population growth."
Auto Clubhouse is an exclusive community of affluent high net-worth auto enthusiasts looking to store their luxury cars. The community offers built-to-suit customizable garages, which will be also constructed by JFB Construction, with high-end security, a members' clubhouse and additional benefits.&nbsp;The first Auto Clubhouse is under construction in Jupiter, Florida. The Company is currently in planning stage for the building of additional Auto Clubhouse locations in Dallas, Texas, Scottsdale, Arizona, and Sarasota, Florida.

JFB Construction Holdings Announces $15M Industrial Construction Of Auto Clubhouse In Charlotte, North Carolina. Project Is Expected To Commence In Q3 2025

Stephens &amp; Co. analyst Andrew Terrell reiterates Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Overweight and maintains $92 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Western Alliance, Maintains $92 Price Target

Wells Fargo analyst Zachary Fadem maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Equal-Weight and lowers the price target from $175 to $170.

TXRH

Wells Fargo Maintains Equal-Weight on Texas Roadhouse, Lowers Price Target to $170

Research Journal Features Genprex Collaborators' Abstract Detailing Positive Preclinical Data on the Use of Reqorsa&#xAE; Gene Therapy for the Treatment of Lung Cancer
AUSTIN, Texas, April 22, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4408078-1&amp;h=2890893948&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published in the online Proceedings supplement of Cancer Research, a scientific journal published by the American Association for Cancer Research (AACR).
&nbsp;
Genprex collaborators will present the published abstract in a poster presentation at the 2025 AACR Annual Meeting being held April 25-30, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data from a study of Genprex's lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC)

Biotech

Penny Stocks

General

GNPX

Genprex Announces Research Collaborators' Abstract Published In Cancer Research Supplement Proceedings On The Use Of Reqorsa Gene Therapy For The Treatment Of Lung Cancer

On Tuesday, Worksport Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) announced first‑quarter gains in its business‑to‑business (B2B) vertical, supported by accelerating demand for the AL4 premium tonneau cover.
The March 2025 B2B sales grew nearly 70% from February. Worksport&#8217;s U.S. network now totals 151 active dealers, a 64 % increase from 92 at year‑end 2024.
Worksport added 35 new dealer accounts in March, following 24 additions in January and February.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/02/43691637/exclusive-kulr-worksport-team-up-to-boost-us-battery-tech-and-domestic-manufacturing" rel="noreferrer noopener">KULR &amp; Worksport Team Up to Boost US Battery Tech and Domestic Manufacturing</a>
By sourcing locally and manufacturing in the U.S., Worksport believes it mitigates tariff risks on its tonneau cover products, supports American jobs, and delivers superior product consistency.
CEO Steven Rossi said the AL4&#8217;s success proves that manufacturing in the U.S. using American aluminum and American workers can out‑compete foreign products.
Worksport&#8217;s dealer partners are independent truck accessory retailers and installers, &#8220;Main Street&#8221; businesses that form the backbone of the U.S. economy.
With over 17,000 addressable dealers nationwide, Worksport expects to see continued growth.
Dealers will likely contribute to notable revenue growth in 2025. Worksport will seek to expand strategically further by partnering with distributors and purchasing groups that value American-made quality and prioritize dealer success. These partnerships would bring many new dealers to the Worksport network.
SOLIS solar-integrated tonneau cover and COR modular portable energy system remain on track for launch later this year, positioning Worksport to capture additional revenue streams in sustainable power solutions, the company said.
Steven Rossi said adding 59 new dealer accounts in three months underscores how strongly American dealers (brick-and-mortar stores) value a high‑margin, U.S.‑made alternative.
Worksport&#8217;s <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43095478/worksport-q4-earnings-246-topline-growth-sets-20-million-revenue-target-for-2025" rel="noreferrer noopener">fourth-quarter 2024</a> revenues rose 246% to $2.9 million, pushing year-end revenue to $8.5 million, exceeding guidance of $6 million-$8 million. The company had previously forecasted further quarterly margin increases, especially towards the second half of 2025.
Price Action: WKSP stock closed lower by 4.85% at $2.55 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44909696/toyota-eyes-us-assembly-of-rav4-in-kentucky-as-a-shield-against-trumps-tariffs" target="_blank" rel="noreferrer noopener">Toyota Eyes US Assembly Of RAV4 In Kentucky As A Shield Against Trump&#8217;s Tariffs</a></li>
</ul>

Earnings

Market-Moving Exclusives

Exclusives

WKSP

EXCLUSIVE: Worksport's March B2B Sales Soar Nearly 70%

Wells Fargo analyst Zachary Fadem maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and lowers the price target from $125 to $100.

SBUX

Wells Fargo Maintains Overweight on Starbucks, Lowers Price Target to $100

EXCUSIVE: Worksport Tells Benzinga Co. Grows Dealer Network 64% In Q1 2025, Says March B2B Sales Increase 70% On US Made AL4 Demand

Stephens &amp; Co. analyst Matt Olney reiterates Southern Missouri Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMBC#NASDAQ">SMBC</a>) with a Overweight and maintains $65 price target.

SMBC

Stephens & Co. Reiterates Overweight on Southern Missouri Bancorp, Maintains $65 Price Target

As of April 22, 2025, two stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Telefonica SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEF#NYSE">TEF</a>)</h3>
<ul>
<li>On Feb. 27, Telefonica posted better-than-expected FY 2024 sales. The company's stock jumped around 11% over the past month and has a 52-week high of $5.05 .</li>
<li>RSI Value: 70.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TEF Price Action: Shares of Telefonica gained 2.2% to close at $5.02 on Monday.</li>
<li>Edge Stock Ratings: 84.76 Momentum score with Value at 31.01. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/TEF"><img loading="lazy" decoding="async" width="495" height="178" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22044725/image-1-17.png" alt="" class="wp-image-881349" style="width:345px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22044725/image-1-17.png 495w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22044725/image-1-17-300x108.png 300w" sizes="(max-width: 495px) 100vw, 495px" /></a></figure>
<h3 class="wp-block-heading">Surgepays Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>)</h3>
<ul>
<li>On March 25, SurgePays reported better-than-expected FY24 sales results. Brian Cox, Chairman and CEO, commented, &#8220;We built the infrastructure. Now we are scaling. With AT&amp;T integration complete and LinkUp Mobile launching nationally, SurgePays is positioned for the most aggressive revenue growth phase in our history.&#8221; The company's stock gained around 103% over the past month and <a href="https://www.benzinga.com/quote/SURG">has a 52-week high</a> of $4.38.</li>
<li>RSI Value: 74.1</li>
<li>SURG Price Action: Shares of Surgepays rose 6.8% to close at $2.66 on Monday.</li>
</ul>
Don't miss out on the full BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">compare all the key stocks now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44895495/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

SURG

Top 2 Tech And Telecom Stocks You May Want To Dump This Quarter

WIIM

OCEA

Ocean Biomedical shares are trading higher after the company announced plans to develop power assets and allocate cash reserves into Bitcoin and Solana.

Health Care

Press Releases

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

Comments

Akoya Biosciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL